Negotiate, price, settle & manage complex deals more efficiently.
PharmaCCX is a communications platform founded by leaders from pharma, payers, and fintech.
We leverage technology and data to help pharma and payers seamlessly manage the entire price negotiation, rebate, and deal management process for complex access agreements such as
Overcome the administrative bottleneck of mounting complex agreements and get a headstart on negotiations.
PharmaCCX’s Contingent Commitment Exchange allows you to express what you really want in a pricing agreement without disclosing important, proprietary information to other parties, unless a deal is reached.
You set contingent commitments (like reserve prices, price volume rebates, performance- or outcome-based provisions).
Our platform finds matches and lets you manage resulting agreements in one place.
We intimately understand your unique challenges and tailormade a solution based on our own needs. With a combined 80 years experience in pharma, finance, business, and tech, our leadership team is poised to help you save more patients’ lives by increasing their access to promising therapies.
A health-tech entrepreneur who formerly co-founded and was CEO of PharmaSecure, which uses serialization to prevent counterfeit drugs from entering the global pharmaceutical supply chain.
A chief lobbyist for the pharma industry in Europe, Sweden’s COVID-19 vaccine coordinator, and former Director General of EFPIA and LIF. He also worked in regulatory affairs at Roche and Novartis.
Highly respected advisor for life science policy and health technology assessment, and former Executive Director of NICE, the National Institute for Health and Care Excellence.
PharmaCCX is an independent, third-party technology platform. We are 100% focused on helping pharma and payers more efficiently reach access agreements so that patients can get the complex therapies they need to survive. We do not take sides — instead, we work collaboratively with all parties involved in a negotiation to help increase patient access to promising, life-saving therapies.